ArticleJournal of medical case reports2026
Acromegalic cardiomyopathy with end-stage heart failure treated with left ventricular assist device: a case report.
Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAcromegaly-related heart failure, as a rare cause of heart failure, presents a substantial healthcare challenge owing to their insidious onset and overlapping symptoms. Current management often includes systemic anti-heart failure treatment and reducing growth hormone(GH) levels, yet cardiac outcomes remain unideal. Left ventricular assist device(LVAD) may be a valuable therapeutic option in such patients. CASE PRESENTATION: We report a case of a 54-year-old Chinese female diagnosed with severe congestive heart failure, classified as New York Heart Association class IV. The clinical symptom failed to improve, despite systemic anti-heart failure treatment. Heart failure arising from acromegaly was suspected due to her facial features, and confirmed through elevated levels of GH and a pituitary macroadenoma demonstrated by magnetic resonance imaging. Upon diagnosis of acromegaly, bromocriptine was initiated to reduce GH levels. Subsequently, our multidisciplinary team administered LVAD implantation, resulted in cardiac symptoms completely relieved within one week postoperatively. During one-year follow-up, the patient's heart condition remained stable and the GH gradually decreased.
conclusionLVAD may be a valuable therapeutic option in acromegaly-related heart failure patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.